Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note released on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price target on shares of Trevena in a report on Thursday, November 14th.

Trevena Trading Up 5.8 %

TRVN stock opened at $1.81 on Monday. The stock’s 50 day simple moving average is $1.71 and its 200 day simple moving average is $3.47. Trevena has a 12-month low of $1.13 and a 12-month high of $19.23. The stock has a market capitalization of $1.56 million, a PE ratio of -0.04 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($5.79) earnings per share (EPS) for the quarter. The firm had revenue of $0.28 million during the quarter. On average, research analysts predict that Trevena will post -23.04 earnings per share for the current year.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.